{"product_id":"new-product-641603","title":"ELISA Kit for Glypican 3 (GPC3)","description":"\u003cp\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/p\u003e\n\u003cp\u003eProduct No.\u003c\/p\u003e\n\u003cp\u003eSEA971Hu\u003c\/p\u003e\n\u003cp\u003eOrganism Species\u003c\/p\u003e\n\u003cp\u003eHomo sapiens (Human).\u003c\/p\u003e\n\u003cp\u003eSample Type\u003c\/p\u003e\n\u003cp\u003eserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids\u003c\/p\u003e\n\u003cp\u003eTest Method\u003c\/p\u003e\n\u003cp\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp\u003eAssay Length\u003c\/p\u003e\n\u003cp\u003e3h\u003c\/p\u003e\n\u003cp\u003eDetection Range\u003c\/p\u003e\n\u003cp\u003e0.156-10ng\/mL\u003c\/p\u003e\n\u003cp\u003eSensitivity\u003c\/p\u003e\n\u003cp\u003eThe minimum detectable dose of this kit is typically less than 0.062ng\/mL.\u003c\/p\u003e\n\u003cp\u003eUOM\u003c\/p\u003e\n\u003cp\u003e48T 96T 96T*5 96T*10 96T*100\u003c\/p\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Glypican 3 (GPC3).\u003cbr\u003eNo significant cross-reactivity or interference between Glypican 3 (GPC3) and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Glypican 3 (GPC3) and the recovery rates were calculated by comparing the measured value to the expected amount of Glypican 3 (GPC3) in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e78-99\u003c\/td\u003e\n\u003ctd\u003e95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e90-104\u003c\/td\u003e\n\u003ctd\u003e94\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e98-105\u003c\/td\u003e\n\u003ctd\u003e101\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glypican 3 (GPC3) were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glypican 3 (GPC3) were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glypican 3 (GPC3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e79-101%\u003c\/td\u003e\n\u003ctd\u003e78-94%\u003c\/td\u003e\n\u003ctd\u003e82-89%\u003c\/td\u003e\n\u003ctd\u003e88-98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e88-101%\u003c\/td\u003e\n\u003ctd\u003e78-94%\u003c\/td\u003e\n\u003ctd\u003e94-105%\u003c\/td\u003e\n\u003ctd\u003e78-96%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e93-101%\u003c\/td\u003e\n\u003ctd\u003e90-104%\u003c\/td\u003e\n\u003ctd\u003e87-94%\u003c\/td\u003e\n\u003ctd\u003e87-97%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-coated, ready to use 96-well strip plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTMB Substrate\u003c\/td\u003e\n\u003ctd\u003e1×9mL\u003c\/td\u003e\n\u003ctd\u003eStop Solution\u003c\/td\u003e\n\u003ctd\u003e1×6mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Prepare all reagents, samples and standards;\u003cbr\u003e2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;\u003cbr\u003e3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;\u003cbr\u003e4. Aspirate and wash 3 times;\u003cbr\u003e5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;\u003cbr\u003e6. Aspirate and wash 5 times;\u003cbr\u003e7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;\u003cbr\u003e8. Add 50µL Stop Solution. Read at 450nm immediately.\u003c\/p\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNature and Science\u003c\/td\u003e\n\u003ctd\u003eDiagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.sciencepub.net\/nature\/ns1004\/006_8707ns1004_32_38.pdf\" target=\"_blank\"\u003eSciencepub:10043238\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Applied Pharmaceutical Science\u003c\/td\u003e\n\u003ctd\u003eCytotoxic effects of antiglypican-3 against HepG2 cell line\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/connection.ebscohost.com\/c\/articles\/94361255\/cytotoxic-effects-antiglypican-3-against-hepg2-cell-line\" target=\"_blank\"\u003eEbscohost: Source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsian Pacific Journal of Cancer Prevention\u003c\/td\u003e\n\u003ctd\u003eCan Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24460300\" target=\"_blank\"\u003ePubmed: 24460300\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClin Biochem.\u003c\/td\u003e\n\u003ctd\u003eDiagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24362268\" target=\"_blank\"\u003ePubmed: 24362268\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScience and Nature\u003c\/td\u003e\n\u003ctd\u003eDiagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/zolcat.com\/press\/journal\/sn\/vol2\/no1\/sn.2.1.2.pdf\" target=\"_blank\"\u003eZolcat: Source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlexandria Journal of Medicine\u003c\/td\u003e\n\u003ctd\u003eRole of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S2090506814000062\" target=\"_blank\"\u003eScienceDirect: S2090506814000062\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ Egypt Natl Canc Inst.\u003c\/td\u003e\n\u003ctd\u003eComparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24841158\" target=\"_blank\"\u003ePubmed:24841158\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Journal of Pharmacology\u003c\/td\u003e\n\u003ctd\u003eEvaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25449037\" target=\"_blank\"\u003ePubmed:25449037\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatobiliary Pancreat Dis Int\u003c\/td\u003e\n\u003ctd\u003ePredictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.hbpdint.com\/CN\/abstract\/abstract4525.shtml\" target=\"_blank\"\u003eabstract:abstract4525.shtml\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical and Molecular Hepatology \u003c\/td\u003e\n\u003ctd\u003eGlypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5066378\/\" target=\"_blank\"\u003epmc:articles\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWiley\u003c\/td\u003e\n\u003ctd\u003eGlypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28621802\" target=\"_blank\"\u003epubmed:28621802\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomedicine \u0026amp; Pharmacotherapy\u003c\/td\u003e\n\u003ctd\u003eCytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29669302\" target=\"_blank\"\u003ePubmed:29669302\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Cancer and Clinical Oncology\u003c\/td\u003e\n\u003ctd\u003eDevelopment and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.researchgate.net\/profile\/Ebtsam_Zaher\/publication\/324128587_Development_and_Validation_of_a_Two-Site_Immunoradiometric_assay_for_Glypican-3_in_plasma_Implication_in_Diagnosis_of_Hepatocellular_Carcinoma_JCCO_Development_and_Validation_of_a_Two\" target=\"_blank\"\u003eResearchgate:Source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurkish journal of oncology\u003c\/td\u003e\n\u003ctd\u003eSerum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.5505\/tjo.2018.1742\" target=\"_blank\"\u003e10.5505:tjo.2018.1742\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntensive Care Medicine Experimental\u003c\/td\u003e\n\u003ctd\u003eElevated plasma glypicans are associated with organ failure in patients with infection\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/link.springer.com\/article\/10.1186\/s40635-018-0216-z\" target=\"_blank\"\u003ePubmed: 30618011\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eVALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC)\u003ca rel=\"nofollow\" href=\"https:\/\/aimj.journals.ekb.eg\/article_69229_69288c14fb5436261a62fac91b6c9971.pdf\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADVANCED RESEARCHES\u003c\/td\u003e\n\u003ctd\u003eSearch for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C\u003ca rel=\"nofollow\" href=\"https:\/\/cyberleninka.ru\/article\/n\/search-for-effective-serum-tumor-markers-for-early-diagnosis-of-hepatocellular-carcinoma-associated-with-hepatitis-c\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife Sci\u003c\/td\u003e\n\u003ctd\u003eSelenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35640776\/\" target=\"_blank\"\u003ePubmed:35640776\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Homo sapiens (Human) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA971Hu02\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA971Hu02.html\"\u003eRecombinant Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA971Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA971Hu01.html\"\u003eRecombinant Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAA971Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/PAA971Hu01.html\"\u003ePolyclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; ICC; IHC-P; IHC-F; ELISA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA971Hu21\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA971Hu21.html\"\u003eMonoclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA971Hu22\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA971Hu22.html\"\u003eMonoclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA971Hu24\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA971Hu24.html\"\u003eMonoclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA971Hu23\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA971Hu23.html\"\u003eMonoclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA971Hu25\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA971Hu25.html\"\u003eMonoclonal Antibody to Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEA971Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEA971Hu.html\"\u003eELISA Kit for Glypican 3 (GPC3)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMA971Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMA971Hu.html\"\u003eMagnetic Luminex Assay Kit for Glypican 3 (GPC3) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"96T \/ The minimum detectable dose of this kit is typically less than 0.057ng\/mL \/ 0.156-10ng\/mL","offer_id":47592211448088,"sku":"SEA971Hu","price":568.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/SE_BIG_4c7a9acb-8c80-4f8d-b9d3-8742810ccfa5.jpg?v=1706237961","url":"https:\/\/danabiosci.com\/products\/new-product-641603","provider":"Dana Bioscience","version":"1.0","type":"link"}